111 related articles for article (PubMed ID: 26260873)
1. Chemotherapy is effective for stage I gastric cancer in patients with synchronous esophageal cancer.
Osumi H; Yoshio T; Chin K; Ogura M; Kumekawa Y; Suenaga M; Matsusaka S; Shinozaki E; Miyamoto Y; Morishige K; Ishiyama A; Hirasawa T; Tsuchida T; Yamamoto Y; Fujisaki J; Igarashi M; Mizunuma N
Gastric Cancer; 2016 Apr; 19(2):625-630. PubMed ID: 26260873
[TBL] [Abstract][Full Text] [Related]
2. A phase II study of adjuvant S-1/cisplatin chemotherapy followed by S-1-based chemoradiotherapy for D2-resected gastric cancer.
Shim HJ; Kim KR; Hwang JE; Bae WK; Ryu SY; Park YK; Nam TK; Chung IJ; Cho SH
Cancer Chemother Pharmacol; 2016 Mar; 77(3):605-12. PubMed ID: 26846507
[TBL] [Abstract][Full Text] [Related]
3. Concurrent chemoradiotherapy for esophageal cancer: comparison between intermittent standard-dose cisplatin with 5-fluorouracil and daily low-dose cisplatin with continuous infusion of 5-fluorouracil.
Sai H; Mitsumori M; Yamauchi C; Araki N; Okumura S; Nagata Y; Nishimura Y; Hiraoka M
Int J Clin Oncol; 2004 Jun; 9(3):149-53. PubMed ID: 15221597
[TBL] [Abstract][Full Text] [Related]
4. A reliable risk score for stage IV esophagogastric cancer.
Blank S; Lordick F; Dobritz M; Grenacher L; Burian M; Langer R; Roth W; Schaible A; Becker K; Bläker H; Sisic L; Stange A; Compani P; Schulze-Bergkamen H; Jäger D; Büchler M; Siewert JR; Ott K
Eur J Surg Oncol; 2013 Aug; 39(8):823-30. PubMed ID: 23375470
[TBL] [Abstract][Full Text] [Related]
5. Postoperative chemotherapy followed by conformal concomitant chemoradiotherapy in high-risk gastric cancer.
Quero L; Bouchbika Z; Kouto H; Baruch-Hennequin V; Gornet JM; Munoz N; Cojean-Zelek I; Houdart R; Panis Y; Valleur P; Aparicio T; Maylin C; Hennequin C
Int J Radiat Oncol Biol Phys; 2012 Jun; 83(2):574-80. PubMed ID: 22099038
[TBL] [Abstract][Full Text] [Related]
6. Complete response to chemoradiotherapy in a patient with synchronous double gastric and esophageal cancer.
Yoshida N; Kochi M; Fujii M; Kanamori N; Kaiga T; Mihara Y; Funada T; Tamegai H; Watanabe M; Takayama T
Anticancer Res; 2011 Jun; 31(6):2339-42. PubMed ID: 21737661
[TBL] [Abstract][Full Text] [Related]
7. Phase I/II study of docetaxel, cisplatin, and 5-fluorouracil combination chemoradiotherapy in patients with advanced esophageal cancer.
Miyazaki T; Sohda M; Tanaka N; Suzuki S; Ieta K; Sakai M; Sano A; Yokobori T; Inose T; Nakajima M; Fukuchi M; Ojima H; Kato H; Kuwano H
Cancer Chemother Pharmacol; 2015 Mar; 75(3):449-55. PubMed ID: 25544126
[TBL] [Abstract][Full Text] [Related]
8. Neoadjuvant chemoradiotherapy with concurrent cisplatin/5-fluorouracil is associated with increased pathologic complete response and improved survival compared to carboplatin/paclitaxel in patients with locally advanced esophageal cancer.
Haisley KR; Hart KD; Nabavizadeh N; Bensch KG; Vaccaro GM; Thomas CR; Schipper PH; Hunter JG; Dolan JP
Dis Esophagus; 2017 Jul; 30(7):1-7. PubMed ID: 28475724
[TBL] [Abstract][Full Text] [Related]
9. [Short-term efficacy and safety of the synchronous neoadjuvant chemoradiotherapy with paclitaxel plus carboplatin in stage III adenocarcinoma of esophagogastric junction].
Ji Y; Peng T; Wang G; Zhang Y; Cao M; Gao Q; Li S
Zhonghua Wei Chang Wai Ke Za Zhi; 2018 Sep; 21(9):1019-1024. PubMed ID: 30269322
[TBL] [Abstract][Full Text] [Related]
10. Expert opinion on management of gastric and gastro-oesophageal junction adenocarcinoma on behalf of the European Organisation for Research and Treatment of Cancer (EORTC)-gastrointestinal cancer group.
Van Cutsem E; Van de Velde C; Roth A; Lordick F; Köhne CH; Cascinu S; Aapro M;
Eur J Cancer; 2008 Jan; 44(2):182-94. PubMed ID: 18093827
[TBL] [Abstract][Full Text] [Related]
11. Preoperative chemotherapy with cisplatin and docetaxel followed by surgery and clip-oriented postoperative chemoradiation in patients with localized gastric or gastroesophageal junction adenocarcinoma: results from a phase II feasibility study.
Spizzo G; Öfner D; de Vries A; Lukas P; Steger G; Pluschnig U; Zacherl J; Widder J; Zabernigg A; Gastl G; Mühlmann G
Ann Surg Oncol; 2011 Mar; 18(3):677-83. PubMed ID: 21063792
[TBL] [Abstract][Full Text] [Related]
12. A phase II trial of induction epirubicin, oxaliplatin, and fluorouracil, followed by surgery and postoperative concurrent cisplatin and fluorouracil chemoradiotherapy in patients with locoregionally advanced adenocarcinoma of the esophagus and gastroesophageal junction.
McNamara MJ; Adelstein DJ; Bodmann JW; Greskovich JF; Ives DI; Mason DP; Murthy SC; Rice TW; Saxton JP; Sohal D; Stephans K; Rodriguez CP; Videtic GM; Rybicki LA
J Thorac Oncol; 2014 Oct; 9(10):1561-7. PubMed ID: 25170643
[TBL] [Abstract][Full Text] [Related]
13. A retrospective comparison of neoadjuvant chemoradiotherapy regimens for locally advanced esophageal cancer.
Sanford NN; Catalano PJ; Enzinger PC; King BL; Bueno R; Martin NE; Hong TS; Wo JY; Mamon HJ
Dis Esophagus; 2017 Jul; 30(7):1-8. PubMed ID: 28475728
[TBL] [Abstract][Full Text] [Related]
14. [A successful resected case of advanced esophageal cancer with early gastric cancer responding to neoadjuvant chemotherapy of docetaxel, CDDP and 5-FU].
Matsutani T; Yoshida H; Sasajima K; Maruyama H; Yokoyama T; Matsushita A; Hirakata A; Takao Y; Umakoshi M; Hayakawa T; Katayama H; Hosone M; Uchida E
Gan To Kagaku Ryoho; 2012 Apr; 39(4):645-8. PubMed ID: 22504694
[TBL] [Abstract][Full Text] [Related]
15. Cisplatin Substitution with Carboplatin During Radical Chemoradiotherapy for Oesophagogastric Carcinoma: Outcomes from a Tertiary Centre.
Athauda A; Watkins D; Mohammed K; Chau I; Starling N; Rao S; Tait D; Aitken K; Cunningham D
Anticancer Res; 2018 Oct; 38(10):5943-5949. PubMed ID: 30275223
[TBL] [Abstract][Full Text] [Related]
16. Adjuvant bi-weekly combination of cisplatin, infusional 5-fluorouracil and folinic acid followed by concomitant chemoradiotherapy with infusional fluorouracil for high risk operated gastric and gastroesophageal junction adenocarcinoma.
Uncu D; Ozdemir NY; Aksoy S; Abali H; Oksuzoglu BC; Budakoglu B; Yildiz R; Aslan N; Zengin N
Asian Pac J Cancer Prev; 2010; 11(6):1493-7. PubMed ID: 21338186
[TBL] [Abstract][Full Text] [Related]
17. [Trastuzumab in combination with chemotherapy versus chemotherapy alone for first-line treatment of HER2-positive advanced gastric or gastroesophageal junction cancer: a Phase III, multi-center, randomized controlled trial, Chinese subreport].
Shen L; Xu JM; Feng FY; Jiao SC; Wang LW; Li J; Guan ZZ; Qin SK; Wang JJ; Yu SY; Wang YJ; Jin YN; Tao M; Zheng LZ; Pan LX
Zhonghua Zhong Liu Za Zhi; 2013 Apr; 35(4):295-300. PubMed ID: 23985260
[TBL] [Abstract][Full Text] [Related]
18. Usefulness of chemoradiotherapy for inoperable gastric cancer.
Taki T; Hoya Y; Watanabe A; Nakayoshi T; Okamoto T; Sekine H; Mitsumori N; Yanaga K
Ann R Coll Surg Engl; 2017 Apr; 99(4):332-336. PubMed ID: 27659357
[TBL] [Abstract][Full Text] [Related]
19. Prognostic factors in definitive radiochemotherapy of advanced inoperable esophageal cancer.
Semrau R; Herzog SL; Vallböhmer D; Kocher M; Hölscher AH; Müller RP
Dis Esophagus; 2012 Aug; 25(6):545-54. PubMed ID: 22133297
[TBL] [Abstract][Full Text] [Related]
20. Clinical results of definitive chemoradiotherapy for patients with synchronous head and neck squamous cell carcinoma and esophageal cancer.
Shinoto M; Shioyama Y; Sasaki T; Nakamura K; Ohura H; Toh Y; Higaki Y; Yamaguchi T; Ohnishi K; Atsumi K; Hirata H; Honda H
Am J Clin Oncol; 2011 Aug; 34(4):362-6. PubMed ID: 20686402
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
